• Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan
• In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available
• Studies such as these are helping Delic drive the conversation on psychedelics forward
• The company seeks to take this conversation further with its participation at this year’s Emerald Conference

Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the pandemic. In addition, spending on mental health treatment has grown by 52% since 2009, currently standing at $225 billion. The growth in these figures has increased the demand for alternatives to current therapies, which have been associated with more side effects and less efficacy (https://ibn.fm/xdzmN).

Delic Holdings (CSE: DELC) (OTCQB: DELCF) recognizes the opportunity within this market and acknowledges the underlying issues affecting people dealing with mental health conditions, specifically in the United States. As a leader in new medicines and treatments for the modern world, the company is pushing for psychedelic-based treatment adoptions and access to an even wider pool of individuals who could benefit significantly from these treatments.

An issue that Delic acknowledges is the lack of access to mental health treatments in general. Most notably, it is estimated that over 112 million Americans live in areas where they cannot access mental health providers, with most establishments located in urban areas.

To remedy the issue, Delic has embarked on an aggressive expansion plan that aims to increase the number of its wellness clinics. In 2021, the company completed the acquisition of Ketamine Wellness Centers (“KWC”), a corporation that operates ketamine infusion clinics across nine states. The purchase increased the number of operational wellness clinics under Delic to 12, making the company the largest owner and operator of the most profitable chain of mental health clinics in the United States.

These clinics are located in secondary cities instead of urban areas. The objective is to improve accessibility and reach, helping as many people with mental health issues as possible. Over the next 18 months, the company seeks to open 14 additional clinics to improve its reach further and help even more people.

Delic is confident in the potential of psychedelics in treating mental health conditions, the reason it is willing to push the conversation forward regarding the adoption of psychedelics as a treatment option. Opening clinics and bringing its products closer to consumers is one way the company is trying to achieve this. The other is by capitalizing on scientific studies to back its claims, sparking the conversation and push for change.

On behalf of Delic, a recently-concluded study conducted by The Harris Poll sought to identify what people think of psychedelic medicine to treat anxiety, depression, and Post-Traumatic Stress Disorder (“PTSD”). It was established that 65% of Americans who suffer from these conditions believe that psychedelic medicine should be made more available to patients, particularly those with treatment-resistant conditions (https://ibn.fm/0tzzG).

The study also showed that 83% of Americans living with mental health conditions are open to pursuing alternative treatments that have proven to be more effective than prescription medications. In addition, 66% would be open to seeking treatment using ketamine, 62% with psilocybin, and 56% with MDMA, if each was proven more effective and with fewer side effects than prescription drugs.

The study, which involved 2,037 adults aged 18 years and above, proved to be an excellent basis for Delic to justify its course and push for the ongoing psychedelic renaissance. The company also seeks to move the conversation even further by leveraging platforms that advance scientific communication and collaboration. 

Delic has big plans for 2022, and it remains optimistic that it will continue leading what has come to be referred to as the psychedelic renaissance.

For more information, visit the company’s website at www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.